[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"catheter-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:catheter-infection":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,87,117,139],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100640666","the-ivcare-adaptive-platform-trial-100640666",false,"NCT07587593","The IVCare Adaptive Platform Trial","Comparative Effectiveness of Interventions to Prevent Infections and Other Complications Arising From Central Venous Access Devices: the IVCare Adaptive Platform Trial.","Core inclusion Criteria:\n\n* The patient has or requires a CVAD, including a PICC, a non-tunnelled or tunnelled CVC, or a totally implanted venous access port.\n* Patient is less than 18 years old and paediatric recruitment has not been approved at the site.\n\nSecurement Domain exclusion criteria:\n\n* Central line-associated bloodstream infection (CLABSI) currently suspected associated with any vascular access device (peripheral or central) that is in situ.\n* CLABSI diagnosed from any vascular access device currently in situ within the past 7 days or being actively treated with antimicrobials.\n* Participants with an estimated life expectancy of \\\u003C30 days OR who have commenced a documented end-of-life, terminal-care, or comfort-care pathway.\n* Participants who have previously been randomised for the same CVAD.\n* Participants who have been randomised three times.\n* SecurAcath® cannot be applied in accordance with manufacturer instructions and local policy.\n* The participant has compromised skin integrity at the current or intended insertion site, including active infection, inflammation, erosion, ulceration, or pre-existing exit-site injury.\n\nConnectors\u002FCaps Domain exclusion criteria:\n\n* Central line-associated bloodstream infection (CLABSI) currently suspected associated with any vascular access device (peripheral or central) that is in situ.\n* CLABSI diagnosed within the past 14 days or CLABSI being actively treated with antimicrobials, associated with any vascular access device currently in situ.\n* Participants with an estimated life expectancy of \\\u003C30 days OR who have commenced a documented end-of-life, terminal-care, or comfort-care pathway.\n* Participants who have previously been randomised for the same CVAD.\n* Participants who have been randomised three times.\n* Known or suspected hypersensitivity or a confirmed allergy to chlorhexidine or silver-containing products.\n\nCancer stratum inclusion criteria:\n\n* Confirmed diagnosis of a solid tumour OR\n* Confirmed diagnosis of a haematological malignancy. OR\n* Bone marrow failure syndrome requiring systemic therapy, immunosuppression, or haematopoietic stem cell transplantation.\n\nKidney stratum exclusion criteria:\n\n• Confirmed diagnosis of kidney disease.","ALL",{"count":18,"type":19},2500,"ESTIMATED","INTERVENTIONAL",[22],"NA","The IVCare trial is a multicentre adaptive platform study evaluating interventions to prevent infections and other complications associated with central venous access devices (CVADs) in patients with newly inserted or existing devices. The study is organised into domains addressing different aspects of CVAD care and includes patient groups referred to as strata. Domains, strata and interventions may change over time as the study progresses. IVCare also includes an observational cohort study in which patients with CVADs are followed to assess CVAD care practices, infections, and other CVAD-related complications across health services.\n\nThe trial starts with two domains. The Connectors\u002FCaps Domain compares antimicrobial chlorhexidine-containing connectors and caps with standard-of-care connectors and caps used in Australian hospitals. In the cancer stratum, participants are randomised to receive either InVision-Plus CS® or standard-of-care connectors\u002Fcaps. In the kidney disease stratum, participants are randomised to receive either ClearGuard™ HD or standard-of-care connectors\u002Fcaps. Following a predefined stopping decision for ClearGuard™ HD in the kidney disease stratum, Tego™ will be introduced and evaluated in this group.\n\nThe Securement Domain compares the effectiveness of SecurAcath®, a subcutaneous anchor securement system, with standard-of-care securement methods used in Australian hospitals. Participants in both the cancer and kidney disease strata are randomised to receive either SecurAcath® or standard-of-care securement.",[25,26,27,28],"Device Related Infection","Vascular Access Complication","Device Related Sepsis","Catheter Infection",[30,31,32,33,34,35],"Central venous access device","Chlorhexidine cap","Chlorhexidine connector","Subcutaneous anchor","Central line-associated blood stream infection","Adaptive platform trial","NOT_YET_RECRUITING","2026-05-07",{"date":39,"type":40},"2026-05-14","ACTUAL",{"date":42,"type":19},"2026-12-01",{"date":44,"type":19},"2031-12-01",{"name":46,"class":47},"The University of Queensland","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":20,"phases":59,"briefSummary":60,"conditions":61,"keywords":68,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},"100594451","chlorhexidine-caps-for-clabsi-prevention-in-hemodialysis-a-pilot-randomized-controlled-trial-100594451","NCT07019610","Chlorhexidine Caps for CLABSI Prevention in Hemodialysis: a Pilot Randomized Controlled Trial","Evaluation of Chlorhexidine Caps for Central Line Associated Blood Stream Infection Prevention in People Needing Hemodialysis: a Pilot Randomised Control Trial","ECHO-HD","Inclusion Criteria:\n\n* Age≥18\n* Able to provide informed consent\n* Kidney failure requiring a tunnelled CVC for treatment (haemodialysis)\n* 21 days BSI free\n* No known allergy to chlorhexidine and\u002For nylon and\u002For polypropylene.\n\nExclusion Criteria:\n\n* Current CLABSI\n* Known allergic to chlorhexidine and\u002For nylon and\u002For polypropylene.\n* Patients on an end-of-life pathway\n* People with a cognitive impairment and\u002For intellectual disability","18 Years",{"count":58,"type":19},60,[22],"The goal of this clinical trial is to compare a chlorhexidine antimicrobial barrier cap in patients requiring hemodialysis treatment to the standard hemodialysis caps currently used within the Metro North Kidney Health Service.\n\nThe main questions to answer are:\n\n* Study Feasibility\n* Occurrence of infectious complications related to renal central venous catheters\n\nParticipants will be randomly allocated to receive either of the below hemodialysis caps to cover their hemodialysis catheter hub:\n\n* The standard hemodialysis cap used at the Royal Brisbane and Women's Hospital, or\n* The intervention hemodialysis cap containing chlorhexidine inside it\n\nResearchers will compare standard and chlorhexidine hemodialysis caps to see if the presence of chlorhexidine improves the occurrance of infectious complications related to the hemodialysis catheter.",[26,25,27,28,62,63,64,65,66,67],"Catheter Complications","Catheter-Related Infections","Catheter Related Complications","Hemodialysis Catheter Infection","Hemodialysis Catheter-associated Infection","Hemodialysis Complication",[69,70,71,72,73,31,74,75,76,77],"Hemodialysis Catheter","Randomised Controlled Trial","Antimicrobial Barrier Caps","Vascular access device","Hemodialysis catheter caps","Central Venous Catheter","CVC","CLABSI","Central Line Associated Blood Stream Infection","2026-04-27",{"date":80,"type":40},"2026-04-29",{"date":82,"type":19},"2026-06",{"date":84,"type":19},"2028-02",{"name":46,"class":47},1,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":94,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":20,"phases":97,"briefSummary":98,"conditions":99,"keywords":102,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":86},"100611333","the-impact-of-irrisept-in-reducing-urinary-tract-infection-during-urethral-catheter-removal-100611333","NCT07239219","The Impact of Irrisept in Reducing Urinary Tract Infection During Urethral Catheter Removal.","To Determine the Efficacy of Irrisept in Reducing Urinary Tract Infection During Urethral Catheter Removal.","Inclusion Criteria:\n\n1. Presenting to the urology clinic for catheter removal\n2. Must be 18 years or older.\n3. The patient must be able to understand and willing to provide informed consent as described in this study protocol.\n4. Must be willing to complete a post-catheter removal survey\n\nExclusion Criteria:\n\n1. Allergy or adverse reaction to chlorohexidine gluconate\n2. Under the age of 18\n3. Refuse to provide informed consent\n4. On antibiotic therapy for any indication.\n5. Women who are pregnant or breastfeeding\n6. Signs of skin or systemic infection\n7. Patients undergoing catheter exchange",true,{"count":96,"type":19},300,[22],"Given the high burden of post-catheter removal UTIs, this study aims to evaluate Irrisept instillation as a non-antibiotic intervention to reduce infection rates. By comparing Irrisept to saline irrigation, the study will provide critical insights into the efficacy of antiseptic bladder irrigation in preventing UTIs while minimizing antibiotic use. If successful, this approach could lead to new clinical guidelines for catheter removal protocols, improving patient outcomes and reducing healthcare costs.",[100,101,28],"Urinary Tract Infection","Antibiotic",[103,104,105,106],"UTI","antibiotic","Catheter infection","CAUTI","RECRUITING","2025-11-16",{"date":110,"type":40},"2025-11-20",{"date":112,"type":19},"2025-12-31",{"date":114,"type":19},"2028-01-01",{"name":116,"class":47},"Ohio State University",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":20,"phases":126,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":86},"100541605","phase-4-gentamicin-bladder-instillation-on-cauti-100541605","NCT06332040","Gentamicin Bladder Instillation on CAUTI","A Randomized Controlled Trial to Evaluate the Effectiveness of Gentamicin Bladder Instillation on CAUTI","Inclusion Criteria:\n\n1. age greater than 18\n2. admitted with a trauma, surgical, or neuro-critical care diagnosis\n3. indwelling foley catheter in place\n\nExclusion Criteria:\n\n1. Documented positive UA or Urine Culture within the past 7 days or upon admission\n2. Traumatic bladder injury\n3. Gross hematuria\n4. Chronic indwelling urethral or chronic suprapubic foley catheter\n5. allergy to gentamicin or similar aminoglycosides",{"count":125,"type":19},400,[127],"PHASE4","Urinary tract infections in catheterized patients is an unacceptable complication and has been termed a 'never event' by the Center for Medicare \\& Medicaid Services (CMS); however there is not consensus among clinicians on how to best prevent CAUTIs. We propose a prospective randomized controlled trial to test the efficacy of prophylactic gentamicin bladder irrigation in elimination of CAUTIs.",[28],"2025-07-08",{"date":132,"type":40},"2025-07-11",{"date":134,"type":40},"2023-10-09",{"date":136,"type":19},"2026-10-08",{"name":138,"class":47},"St. Joseph's Hospital and Medical Center, Phoenix",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":16,"minAge":147,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":20,"phases":150,"briefSummary":151,"conditions":152,"keywords":160,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":86},"100588234","novel-medical-device-for-pharmacological-therapy-100588234","NCT06938750","Novel Medical Device for Pharmacological Therapy","A Pilot Study of a Novel Medical Device for Pharmacological Therapy: The SecHold Device","Sechold","Inclusion Criteria:\n\n* patients admitted to the intensive care unit\n* patients with authorization to take part in the study\n\nExclusion Criteria:\n\n* Patients with pre-existing medical conditions: Patients with diseases affecting coagulation, such as hemophilia or thrombocytopathies, could be excluded.\n* Active infection patients: Any patient with vascular access site infections or systemic infections may be excluded to avoid complications.\n* Inability to give informed consent: Patients who are unable to understand or consent to participate in the study.","1 Year",{"count":149,"type":19},262,[22],"Background: Different co-creation methods were used to design and prototype a new fixative device for multiple intravenous therapies with the ability to control and identify the pharmacological therapy administered to a patient. Objectives: To validate a newly created device for the reduction of complications related to the use of intravenous therapy Methods: A multidisciplinary team composed of eight professionals specializing in the field of critical care and an engineering professional in industrial design was responsible for collecting, evaluating, and materializing the ideas and needs arising from clinical practice in a device that met the standards of the same.",[153,26,154,155,28,156,157,158,159],"Vascular Access","Vascular Access Complications","Catheter Malfunction","Therapeutic Drug Management","Nurse","Nurse Based Care Management","Innovative Procedures",[161,162,163,164,165,166],"VASCULAR ACCESS","CATHETER","THERAPY","COMPLICATION","DEVICE","CENTRAL VASCULAR ACCESS","2025-04-14",{"date":169,"type":40},"2025-04-22",{"date":171,"type":40},"2023-01-20",{"date":173,"type":19},"2026-09-20",{"name":175,"class":47},"Fundacion Miguel Servet"]